Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.

Wang H, Bauzon F, Ji P, Xu X, Sun D, Locker J, Sellers RS, Nakayama K, Nakayama KI, Cobrinik D, Zhu L.

Nat Genet. 2010 Jan;42(1):83-8. doi: 10.1038/ng.498. Epub 2009 Dec 6.

2.

Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity.

Lu Z, Bauzon F, Fu H, Cui J, Zhao H, Nakayama K, Nakayama KI, Zhu L.

Nat Commun. 2014 Mar 17;5:3463. doi: 10.1038/ncomms4463.

3.

p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.

Zhao H, Lu Z, Bauzon F, Fu H, Cui J, Locker J, Zhu L.

Oncogene. 2017 Jan 5;36(1):60-70. doi: 10.1038/onc.2016.175. Epub 2016 May 16.

4.

Substituting threonine 187 with alanine in p27Kip1 prevents pituitary tumorigenesis by two-hit loss of Rb1 and enhances humoral immunity in old age.

Zhao H, Bauzon F, Bi E, Yu JJ, Fu H, Lu Z, Cui J, Jeon H, Zang X, Ye BH, Zhu L.

J Biol Chem. 2015 Feb 27;290(9):5797-809. doi: 10.1074/jbc.M114.625350. Epub 2015 Jan 12.

5.

Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Bauzon F, Zhu L.

Cell Cycle. 2010 Jun 1;9(11):2118-23. Epub 2010 Jun 1. Review.

6.

Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.

Zhao H, Wang H, Bauzon F, Lu Z, Fu H, Cui J, Zhu L.

J Biol Chem. 2016 May 6;291(19):10201-9. doi: 10.1074/jbc.M116.718049. Epub 2016 Mar 10.

7.
8.

Renal damage in obstructive nephropathy is decreased in Skp2-deficient mice.

Suzuki S, Fukasawa H, Kitagawa K, Uchida C, Hattori T, Isobe T, Oda T, Misaki T, Ohashi N, Nakayama K, Nakayama KI, Hishida A, Yamamoto T, Kitagawa M.

Am J Pathol. 2007 Aug;171(2):473-83. Epub 2007 Jul 9.

9.

Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors.

Zhao H, Bauzon F, Fu H, Lu Z, Cui J, Nakayama K, Nakayama KI, Locker J, Zhu L.

Cancer Cell. 2013 Nov 11;24(5):645-59. doi: 10.1016/j.ccr.2013.09.021.

10.

A Skp2 autoinduction loop and restriction point control.

Yung Y, Walker JL, Roberts JM, Assoian RK.

J Cell Biol. 2007 Aug 27;178(5):741-7.

11.

Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.

Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D, Zi X.

Oncotarget. 2015 Dec 8;6(39):41809-24. doi: 10.18632/oncotarget.6166.

12.

SKP2 Activation by Thyroid Hormone Receptor β2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells.

Xu XL, Li Z, Liu A, Fan X, Hu DN, Qi DL, Chitty DW, Jia R, Qui J, Wang JQ, Sharaf J, Zou J, Weiss R, Huang H, Joseph WJ, Ng L, Rosen R, Shen B, Reid MW, Forrest D, Abramson DH, Singer S, Cobrinik D, Jhanwar SC.

Cancer Res. 2017 Dec 15;77(24):6838-6850. doi: 10.1158/0008-5472.CAN-16-3299. Epub 2017 Sep 28.

PMID:
28972075
13.

S-phase kinase-associated protein 2 knockdown blocks colorectal cancer growth via regulation of both p27 and p16 expression.

Xu SY, Wang F, Wei G, Wang B, Yang JY, Huang YZ, Zhang L, Zheng F, Guo LY, Wang JN, Tang JM.

Cancer Gene Ther. 2013 Dec;20(12):690-4. doi: 10.1038/cgt.2013.70. Epub 2013 Dec 13.

PMID:
24336114
14.

Skp2-RNAi suppresses proliferation and migration of gallbladder carcinoma cells by enhancing p27 expression.

Zhang B, Ji LH, Liu W, Zhao G, Wu ZY.

World J Gastroenterol. 2013 Aug 14;19(30):4917-24. doi: 10.3748/wjg.v19.i30.4917.

15.

Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation.

Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M, Takata T.

Mol Cancer Ther. 2005 Mar;4(3):471-6.

16.

EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein.

Huang HC, Way TD, Lin CL, Lin JK.

Endocrinology. 2008 Dec;149(12):5972-83. doi: 10.1210/en.2008-0408. Epub 2008 Aug 21.

PMID:
18719023
17.

Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.

Old JB, Kratzat S, Hoellein A, Graf S, Nilsson JA, Nilsson L, Nakayama KI, Peschel C, Cleveland JL, Keller UB.

Mol Cancer Res. 2010 Mar;8(3):353-62. doi: 10.1158/1541-7786.MCR-09-0232. Epub 2010 Mar 2.

18.

The amelioration of renal damage in Skp2-deficient mice canceled by p27 Kip1 deficiency in Skp2-/- p27-/- mice.

Suzuki S, Fukasawa H, Misaki T, Togawa A, Ohashi N, Kitagawa K, Kotake Y, Liu N, Niida H, Nakayama K, Nakayama KI, Yamamoto T, Kitagawa M.

PLoS One. 2012;7(4):e36249. doi: 10.1371/journal.pone.0036249. Epub 2012 Apr 27.

19.

Skp2 deficiency inhibits chemical skin tumorigenesis independent of p27(Kip1) accumulation.

Sistrunk C, Kim SH, Wang X, Lee SH, Kim Y, Macias E, Rodriguez-Puebla ML.

Am J Pathol. 2013 May;182(5):1854-64. doi: 10.1016/j.ajpath.2013.01.016. Epub 2013 Mar 6.

20.

c-myc and skp2 coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-related protein.

Sicari BM, Troxell R, Salim F, Tanwir M, Takane KK, Fiaschi-Taesch N.

Endocrinology. 2012 Feb;153(2):861-72. doi: 10.1210/en.2011-1590. Epub 2011 Dec 30.

PMID:
22210745

Supplemental Content

Support Center